Johannesburg, 21 June21: The United States Food and Drug Administration (FDA) has approved the first new drug developed for Alzheimer’s Disease in over 20 years – but the decision and the drug itself appear to be controversial. The drug, known as Aduhelm (scientific name: aducanumab) has been developed by the Cambridge, Massachusetts based company Biogen together with Japanese company Eisai Co. Its approval appears to hinge on the fact that U.S. regulators believe it is the only one that could treat the underlying disease, rather than manage symptoms.
The purpose of the drug is to clear harmful accumulations of a protein called beta-amyloid from the brain. This naturally-occurring protein appears to be abnormally high in the brains of Alzheimer’s patients, causing it to clump together to form plaques that collect between neurons and disrupt cell function, which in turn leads to cell death. Initially, Alzheimer’s disease tends to destroy neurons and their connections in parts of the brain used for memory. It later affects areas in the cerebral cortex responsible for language, reasoning, and social behaviour. In the long term, many other areas of the brain are damaged, leading to the patient losing their ability to function independently.
There is controversy over Aduhelm, however, because independent advisors to the FDA have warned that the treatment has not conclusively been shown to slow the progression of dementia. The drug does not reverse mental decline, and only one study seems to have indicated that it may slow it. The FDA is requiring that the drug-maker conduct further studies to confirm the benefit of the drug for patients. If it fails to prove effective, it could be pulled from the market.
Why approve a drug if there is still such controversy surrounding it? The FDA believes that the potential benefits outweigh the risks, because there is such a great unmet need for effective Alzheimer’s treatments. According to Alzheimer’s News Today, there are an estimated 44 million people worldwide living with Alzheimer’s Disease or a related form of dementia. Reports from America’s National Institute on Aging indicate that one’s chance of Alzheimer’s Disease doubles every five years after age 65. However, around one in 20 people with the disease are under 65. Early-onset Alzheimer’s can affect people as young as 40. American statistics show that more than half of people over age 85 living in the USA suffer from dementia.
If these statistics do not seem alarming enough, consider that the global cost of Alzheimer’s disease and dementia is estimated to be US$605 billion, which is equivalent to one percent of the entire world’s gross domestic product.
There is currently no effective cure or treatment for Alzheimer’s Disease, so one can understand the reason for the controversy. On the one hand, approving a drug that has not yet proven its benefits conclusively could set a dangerous precedent. On the other hand, groups representing Alzheimer’s patients and their families say that any new therapy, even if it has small benefit, warrants approval.
How this will play out remains to be seen. It is encouraging to see a revival of research into Alzheimer’s treatments, most of which have failed in the past. For most people living with the disease right now, however, this is of little help. “Regardless of what medication is available, it is important to plan for the long-term needs of people suffering from dementia,” says Barry Kaganson, CEO of Auria Senior Living, which develops gold-standard senior living communities in South Africa. Auria’s flagship community, San Sereno in Bryanston, Johannesburg, has a state-of-the-art dementia care facility and its staff are well-versed in caring for patients with the condition.
“Specialised care is required for people living with dementia,” says Kaganson. “We believe the best environment is a residential setting which is properly tailored to their needs. Such an environment provides staff who are trained to deal with their particular requirements and offers appropriate and meaningful activities and wellness programmes. Such an environment not only reduces symptoms like anxiety in patients, but it also removes the stress on their families – which can be considerable given that their home environments are not well suited to the needs of the patient, and family members are often not trained to provide the right care.”
Whether Aduhelm proves to be effective for treating Alzheimer’s Disease or not, one’s best course of action for a relative with dementia is to provide them with a comfortable and supportive setting, and to enable them to live a meaningful life. Assisted living environments are often the best option as they can provide the right support. “Many dementia sufferers can still live a life of interest and meaning – often without excessive medication. A caring and compassionate environment where help is provided with aspects of daily living such as routine, exercise, balanced diet and healthy activity can still give a person quality of life despite their condition,” says Kaganson.
About Auria Senior Living
Auria Senior Living (Auria) develops, owns and manages a portfolio of senior living communities throughout South Africa. Auria is setting a new benchmark in continuing-care community living for the over-70s, providing for the intellectual, emotional, social and physical needs of its residents, in attractive and well-located environments.
The company’s flagship is San Sereno in Bryanston, and it has just upgraded Melrose Manor in Melrose North. Its latest project, Royal View, is a 122 apartment senior living development on the Royal Johannesburg & Kensington golf course, due to open in 2022, with sales commencing in the 2nd quarter of 2021. Woodside Village, Auria’s first senior living environment in the Western Cape, is currently being refurbished and is expected to be complete before the end of 2021. Further Auria communities are planned across the country.
For more information on Auria Senior Living, visit: www.auria.co.za, or contact 087 654 8833.
Mantis Communications | Tel: 079 438 3252